The Current Ratio as of December 2024 (TTM) for BioCryst Pharmaceuticals, Inc. (BCRX) is 2.78

According to BioCryst Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.78. This represents a change of -11.93% compared to the average of 3.16 of the last 4 quarters.

BioCryst Pharmaceuticals, Inc. (BCRX) Historical Current Ratio (quarterly & annually)

How has BCRX Current Ratio performed in the past?

The mean historical Current Ratio of BioCryst Pharmaceuticals, Inc. over the last ten years is 2.56. The current 2.78 Current Ratio has changed 10.75% with respect to the historical average. Over the past ten years (40 quarters), BCRX's Current Ratio was at its highest in in the March 2022 quarter at 6.32. The Current Ratio was at its lowest in in the March 2016 quarter at 0.80.

BioCryst Pharmaceuticals, Inc. (BCRX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of BioCryst Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

BioCryst Pharmaceuticals, Inc. (BCRX) Average Current Ratio

How has BCRX Current Ratio performed in the past?

The current Current Ratio of BioCryst Pharmaceuticals, Inc. (BCRX) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

BioCryst Pharmaceuticals, Inc. (BCRX) Current Ratio vs. Peers

How is BCRX’s Current Ratio compared to its peers?

BioCryst Pharmaceuticals, Inc.’s Current Ratio is less than TG Therapeutics, Inc. (4.59), greater than Axsome Therapeutics, Inc. (2.44), less than Intercept Pharmaceuticals, Inc. (4.22), greater than Seres Therapeutics, Inc. (1.12), less than Madrigal Pharmaceuticals, Inc. (5.98), less than Kezar Life Sciences, Inc. (7.65), greater than Immunic, Inc. (2.71), greater than Atara Biotherapeutics, Inc. (0.59), less than Pieris Pharmaceuticals, Inc. (4.82), less than Apellis Pharmaceuticals, Inc. (4.36), less than Blueprint Medicines Corporation (3.32), less than Karuna Therapeutics, Inc. (19.31), less than Mirati Therapeutics, Inc. (7.54), less than Day One Biopharmaceuticals, Inc. (14.62), less than Anavex Life Sciences Corp. (12.04), less than Cassava Sciences, Inc. (3.55), greater than INmune Bio, Inc. (2.59), less than BioVie Inc. (2.95), greater than Cognition Therapeutics, Inc. (2.11), less than Viking Therapeutics, Inc. (36.47), less than X4 Pharmaceuticals, Inc. (4.89), less than PDS Biotechnology Corporation (2.84),

Build a custom stock screener for BioCryst Pharmaceuticals, Inc. (BCRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioCryst Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BioCryst Pharmaceuticals, Inc. (BCRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BioCryst Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.